NovoCure Limited
NVCR · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $655M | $605M | +8.3% |
| Operating income | −$154M | −$170M | +9.8% |
| Net income | −$136M | −$169M | +19.2% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Oct 29, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $193M | $167M | +15.7% |
| Operating income | −$6.20M | −$36.0M | +82.8% |
| Net income | −$10.4M | −$37.3M | +72.1% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was NovoCure's revenue in FY2025?
- $655M in FY2025 (Fiscal year ended Dec 31, 2025), +8.3% vs $605M a year earlier, per its 10-K filed Feb 2026.
- Was NovoCure profitable in FY2025?
- No: net income was −$136M and operating income −$154M in FY2025.
- What was NovoCure's revenue in Q3 2026?
- $193M (+15.7% vs a year earlier), per its Form 10-Q filed Oct 29, 2026.